Asset Management One Co. Ltd. Acquires 2,593 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Asset Management One Co. Ltd. increased its holdings in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 14.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,453 shares of the company's stock after buying an additional 2,593 shares during the period. Asset Management One Co. Ltd.'s holdings in BeiGene were worth $4,592,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Janney Montgomery Scott LLC grew its stake in shares of BeiGene by 63.7% during the first quarter. Janney Montgomery Scott LLC now owns 2,280 shares of the company's stock worth $357,000 after buying an additional 887 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in BeiGene during the 1st quarter valued at approximately $209,000. Oppenheimer Asset Management Inc. lifted its position in shares of BeiGene by 9.1% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 18,124 shares of the company's stock worth $2,834,000 after purchasing an additional 1,507 shares during the period. Headlands Technologies LLC acquired a new stake in BeiGene during the first quarter worth approximately $50,000. Finally, ProShare Advisors LLC boosted its stake in BeiGene by 8.1% during the first quarter. ProShare Advisors LLC now owns 2,902 shares of the company's stock worth $454,000 after acquiring an additional 217 shares in the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BGNE has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on shares of BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a research note on Tuesday, October 22nd. Citigroup boosted their price objective on BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Finally, JMP Securities initiated coverage on BeiGene in a report on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 price target for the company. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $246.21.

Insider Transactions at BeiGene

In other news, CEO John Oyler sold 6,175 shares of the company's stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, SVP Chan Henry Lee sold 1,202 shares of the business's stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $237.10, for a total transaction of $284,994.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John Oyler sold 6,175 shares of the company's stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. Insiders sold a total of 23,070 shares of company stock valued at $4,901,050 in the last quarter. 7.43% of the stock is owned by insiders.

BeiGene Stock Performance

Shares of NASDAQ:BGNE traded down $1.35 during trading on Friday, hitting $205.47. The stock had a trading volume of 207,402 shares, compared to its average volume of 323,515. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $248.16. The firm's fifty day moving average is $212.41 and its 200 day moving average is $180.40.

BeiGene (NASDAQ:BGNE - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, topping the consensus estimate of ($2.27) by $1.12. The business had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. BeiGene's quarterly revenue was up 56.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($3.64) earnings per share. As a group, sell-side analysts predict that BeiGene, Ltd. will post -5 EPS for the current year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.